A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy [Breast Cancer]
Conclusion
The primary end point, PFS based on investigator-determined PD, did not meet noninferiority criteria. As a consistency assessment with the primary finding, PFS based on independent review committee–determined PD met noninferiority criteria. Overall, this study did not achieve noninferiority objective in ruling out a 15% increased risk in PD/death. RBC transfusion should be the preferred approach for the management of anemia in this population.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Leyland-Jones, Bondarenko, Nemsadze, Smirnov, Litvin, Kokhreidze, Abshilava, Janjalia, Li, Lakshmaiah, Samkharadze, Tarasova, Mohapatra, Sparyk, Polenkov, Vladimirov, Xiu, Zhu, Kimelblatt, Deprince, Safonov, Bowers, Vercammen Tags: Chemotherapy, Clinical Trials, Quality of Life Breast Cancer Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Epogen | Procrit | Study | Women